Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01396421 · ClinicalTrials.gov registry record · Phase 3
Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia
A Phase 3 study of Acute Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 636
- Enrollment target
- 20
- Study locations
NCT01396421 is a Phase 3 study of Acute Schizophrenia that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 636 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT01396421, a Phase 3 study of Acute Schizophrenia, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 636 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the effectiveness, safety and tolerability of three different doses of OPC-34712 with placebo in the treatment of acute schizophrenia in adults.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG OPC-34712 [Brexpiprazole] High Dose
- DRUG Experimental: OPC-34712 [Brexpiprazole] Middle Dose
- DRUG Experimental: OPC-34712 [Brexpiprazole] Low Dose
Study Locations (20)
California
- - Garden Grove
- - Glendale
- - Oakland
- - Oceanside
- - San Diego
- - San Diego
Florida
- - Bradenton
- - Miami Springs
- - Orlando
Ontario
- - Burlington
- - Chatham
- - Chatham
New York
- - Fresh Meadows
- - Jamaica
South Carolina
- - Charleston
- - Charleston
Arkansas
- - Little Rock
Ohio
- - Dayton
Texas
- - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 636 participants |
| Start Date | 2011-07 |
| Est. Completion | 2014-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01396421
The ClinicalTrials.gov registry entry for NCT01396421 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 636 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Schizophrenia appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01396421 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Ontario.
Frequently Asked Questions
What is clinical trial NCT01396421 about?
NCT01396421 is a clinical study titled "Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia". The purpose of this study is to compare the effectiveness, safety and tolerability of three different doses of OPC-34712 with placebo in the treatment of acute schizophrenia in adults.
What is the current status of trial NCT01396421?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 636 participants. The study started on 2011-07. Estimated completion is 2014-01.
What conditions does trial NCT01396421 study?
This clinical trial studies the following conditions: Acute Schizophrenia.
What interventions are being tested in trial NCT01396421?
The interventions under investigation include: Placebo (DRUG), OPC-34712 [Brexpiprazole] High Dose (DRUG), Experimental: OPC-34712 [Brexpiprazole] Middle Dose (DRUG), Experimental: OPC-34712 [Brexpiprazole] Low Dose (DRUG).
Who is sponsoring clinical trial NCT01396421?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01396421 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.